- Home
- VEL vs VSTM Comparison
VEL vs VSTM Comparison
Compare VEL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | VSTM |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.4M | 723.8M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VEL | VSTM |
|---|---|---|
| Price | $19.80 | $7.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $21.75 | $13.38 |
| AVG Volume (30 Days) | 76.1K | ★ 2.2M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.26 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $229,360,000.00 | $13,379,000.00 |
| Revenue This Year | $5.75 | $183.10 |
| Revenue Next Year | $27.31 | $271.39 |
| P/E Ratio | $8.04 | ★ N/A |
| Revenue Growth | ★ 116.81 | 33.79 |
| 52 Week Low | $16.12 | $3.46 |
| 52 Week High | $20.98 | $11.25 |
Technical Indicators
Market Signals| Indicator | VEL | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 60.30 | 33.40 |
| Support Level | $19.12 | $9.13 |
| Resistance Level | $20.15 | $9.91 |
| Average True Range (ATR) | 0.59 | 0.62 |
| MACD | 0.02 | -0.32 |
| Stochastic Oscillator | 63.08 | 6.43 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.